The team reviewed 25 past trials that included over 8000 participants, and say those people who were taking GLP-1s also reported moderate reductions in the severity of their binge eating when compared with people not on the meds, or on other weight-loss medications
Comprehensive genomic profiling using a hybrid capture-based DNA+RNA sequencing platform (Caris Life Sciences) revealed a PRKAR1A p.S321fs* pathogenic frameshift mutation (RefSeq transcript NM_001276289.1
1000mg daily dosage for skin clarity, repair, and cellular protection
By the end of the trial period, average results showed: Those on a 4 mg dose lost 47.2 pounds (lb), or about 19 percent of their starting body weight
More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1. Seeking confirmation The results were so surprising, Gloyns team spent the next several years confirming them